Understanding Public Attitudes Towards the COVID-19 Vaccination

NCT ID: NCT05023512

Last Updated: 2022-06-06

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-28
• Study Completion Date: 2022-09-01

Brief Summary

The objective of this study is to better understand public attitudes towards coronavirus disease 2019 (COVID-19) vaccination. This understanding will inform the development of community engagement strategies to be used in future interventions and studies aimed at addressing factors that impact the disproportionate burden of COVID-19 in under-served and vulnerable communities.

Detailed Description

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly instigated a global pandemic. As of this writing, there are more than 33 million documented cases of infection in the United States (US). Furthermore, in the US, COVID-19 has disrupted the economy, overwhelmed the healthcare system, led to widespread school cancellations, and caused more than 595,000 deaths since March 2020.

The availability of three highly effective vaccines against COVID-19 within a year of the start of the pandemic is an extraordinary achievement and cause for great optimism. However, a significant proportion of adults in the U.S. have not accepted vaccination against COVID-19. Efforts are needed to identify effective messages and communication strategies to overcome COVID-19 vaccine hesitancy.

To address this need, the investigators plan to conduct two rapid surveys among Massachusetts residents, to assess attitudes towards COVID-19 vaccination.

Conditions

Covid19; Vaccination

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Message 1

Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.

Group Type: EXPERIMENTAL

Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health

Intervention Type: BEHAVIORAL

Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.

Message 2

Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.

Group Type: EXPERIMENTAL

Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health

Intervention Type: BEHAVIORAL

Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.

Interventions

Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health

Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Massachusetts resident
• Adult (age 18 and over)
• English or Spanish speaking

Exclusion Criteria

• Non-English or Spanish speaking

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston University

OTHER

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

University of Massachusetts, Worcester

OTHER

Sponsor Role: lead

Responsible Party

Kimberly Fisher

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kimberly Fisher, MD

Role: PRINCIPAL_INVESTIGATOR

University of Massachusetts, Worcester

Other Identifiers

1OT2HL156812-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

H00023672

Identifier Type: -

Identifier Source: org_study_id